CLAIMS:

1. Use of an effective amount of docosapentaenoic acid (DPA) in the manufacture of a medicament for enhancing low mood of a peri-partum woman.

2. Use of an effective amount of at least one polyunsaturated fatty acid (PUFA) selected from the group consisting of DPA, eicosapentaenoic acid (EPA), arachidonic acid (AA) and docosahexaenoic acid (DHA) in the manufacture of a medicament for enhancing socio-emotional outcome of a child, wherein the medicament is to be administered antenatally to the child's mother.

3. The use according to Claim 2 wherein the enhancing is related to attention problems.

4. The use according to Claim 2 wherein the enhancing is related to a pervasive developmental problem and the at least one PUFA is EPA or DPA.

5. The use according to Claim 2 wherein the enhancing is related to emotional reactivity problems and the PUFA is DPA.

6. The use according to Claim 2 wherein the enhancing is related to anxiety.

7. The use according to Claim 2 wherein the enhancing is related to at least one component selected from the group consisting of: inattention, hyperactivity, and impulsivity, and the PUFA is DPA.

8. The use according to any of Claims 1-7 wherein the PUFA is DPA and the daily dose is from 1 to 50 mg, preferably from about 2 to 25 mg, and more preferably from 5 to 10 mg.

9. The use according to Claim 8 wherein the daily dose is 5 mg.

10. The use according to Claim 8 wherein the daily dose is 10 mg.

11. A maternal nutritional supplement comprising DPA in a tablet or capsule form.